| 2025-11-06 |
详情>>
股本变动：
变动后总股本9850.93万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.56美元,归母净利润-1.33亿美元,同比去年增长-80.36%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘后发布财报
|
| 2025-09-25 |
详情>>
内部人交易：
Karlin Daniel等共交易3笔
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益-0.78美元,归母净利润-6609.2万美元,同比去年增长-9.69%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.27美元,归母净利润-2334.8万美元,同比去年增长57.08%
|
| 2025-04-23 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.To elect Carol A. Vallone, Andreas Krebs, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska and Robert Barrow to the Company’s board of directors (the “Board of Directors” or the “Board”) to hold office until the 2026 annual general meeting of shareholders ;
2.To appoint KPMG LLP (“KPMG”) as independent registered public accounting firm (auditor) for the Company until the 2026 annual general meeting of shareholders ;
3.To consider, and if deemed advisable, approve the Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan (the “2025 Equity Incentive Plan”), a copy of which is attached as Annex B to the proxy statement accompanying this Notice ;
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-1.54美元,归母净利润-1.09亿美元,同比去年增长-13.52%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.12美元,归母净利润-7393.8万美元,同比去年增长-2.88%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-1.01美元,归母净利润-6025.4万美元,同比去年增长-11.7%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-1.14美元,归母净利润-5440万美元,同比去年增长-119.22%
|
| 2024-04-26 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.To elect Carol A. Vallone, Andreas Krebs, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska and Robert Barrow, to the Company’s board of directors (the “Board of Directors” or the “Board”) to hold office until the 2025 annual general meeting of shareholders (“Proposal No. 1”);
2.To appoint KPMG LLP as independent registered public accounting firm (auditor) for the Company until the 2025 annual general meeting of shareholders (“Proposal No. 2”);
3.To consider, and if deemed advisable, approve the Mind Medicine (MindMed) Inc. 2024 Employee Share Purchase Plan (the “ESPP”), a copy of which is attached as Annex B to the proxy statement accompanying this Notice (“Proposal No. 3”);
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-2.44美元,归母净利润-9573.2万美元,同比去年增长-68.55%
|
| 2023-12-14 |
复牌提示：
2023-12-14 07:25:00 停牌，复牌日期 2023-12-14 08:00:00
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.85美元,归母净利润-7186.8万美元,同比去年增长-38.49%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-1.41美元,归母净利润-5394.5万美元,同比去年增长-52.35%
|
| 2023-05-03 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To elect FCM’s four (4) director nominees, Farzin Farzaneh, Dr. Scott Freeman, Vivek Jain and Alexander J. Wodka (collectively, the “FCM Nominees”), to the Board to hold office until the 2024 annual general meeting of shareholders (the “2024 Annual Meeting”);
2.To appoint KPMG LLP as independent registered public accounting firm (the “Auditor”) for the Company until the close of the 2024 annual general meeting of shareholders;
3.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2022-08-29 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2022-04-18 |
股东大会：
将于2022-05-30召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Carol A. Vallone, Andreas Krebs, Brigid A. Makes, Robert Barrow and Dr. Miri Halperin Wernli, to the Board of Directors to hold office until the 2023 annual general meeting of shareholders;
2.To appoint KPMG LLP as independent registered public accountants (the “Auditor”) for the Company to hold office until close of the 2023 annual general meeting of Shareholders and to authorize the Company’s Board of Directors to fix the auditor’s remuneration;
3.To approve an alteration to the Company’s share structure to eliminate the Multiple Voting Shares and re-designate the Subordinate Voting Shares as Common Shares;
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1.to receive the audited consolidated financial statements of MindMed for the year ended December 31, 2020, together with the report of the auditors thereon;
2.to fix the number of directors to be elected at the Meeting at six;
3.to elect directors of MindMed to hold office until the next meeting of Shareholders at which the election of directors is considered, unless such director resigns or is removed;
4.to appoint auditors of MindMed for the ensuing year and to authorize the board of directors of MindMed to fix their remuneration;
5.to consider and, if deemed appropriate, approve, with or without variation, a special resolution authorizing the Corporation to amend and restate the articles of the Corporation, which include certain amendments to the articles of the Corporation, including (a) the adoption of certain advance notice provisions, (b) the removal of certain restrictions regarding the conversion of Multiple Voting Shares to Subordinate Voting Shares, and (c) certain other corporate maintenance matters, as more particularly described in the accompanying management information circular of the Corporation (the “Circular”);
6.to consider and, if deemed appropriate, approve, with or without variation, an ordinary resolution authorizing the Corporation to increase the percentage of Subordinate Voting Shares reserved under the Corporation’s share option plan and its performance share unit and restricted share unit compensation plan to an aggregate of 15% of the Corporation’s issued and outstanding Subordinate Voting Shares, as more particularly described in the Circular;
7.to transact such other business as may be properly brought before the Meeting or any adjournment thereof.
|